Objective:

To evaluate the European Medicines Agency's (EMA) performance and adaptability during the challenges of 2020, particularly in response to the COVID-19 pandemic.

Approach:

• Report Overview: The EMA released a report in June 2021 detailing its management of key issues in 2020, including the COVID-19 pandemic and antimicrobial resistance.
• Leadership Insight: Christa Wirthumer-Hoche, Chair of the EMA Management Board, highlighted the agency's adaptability during the pandemic and its relocation to the Netherlands.

Key Findings:

• The EMA successfully adapted its activities and processes in response to the COVID-19 pandemic.
• The agency maintained its core activities to protect public health during the transition period.

Interpretation:

Conclusion:

The report reflects the EMA's achievements and adaptability in 2020.

Sources:

• EMA Report